V 270

Drug Profile

V 270

Alternative Names: HBsAg-1018; HBV vaccine preventative - Dynavax; HBV-ISS preventative vaccine; Hepatitis B vaccine 1018-ISS conjugate - Dynavax; Hepatitis B vaccine preventative - Dynavax; HEPLISAV; HEPLISAV-B; V270

Latest Information Update: 01 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dynavax Technologies
  • Class Hepatitis B vaccines
  • Mechanism of Action Immunostimulants; Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Hepatitis B

Most Recent Events

  • 03 Aug 2017 PDUFA action date extended by US FDA to (10/11/2017) for V 270 for Hepatitis (IM, Injection)
  • 28 Jul 2017 Dynavax plans to launch V 270 for Hepatitis B in USA in early 2018
  • 28 Jul 2017 The US FDA' s Vaccines and Related Biological Products Advisory Committee (VRBPAC) votes 12 to 1 that the safety data for HEPLISAV-B™ support licensure for immunization against hepatitis B infection in adults 18 years of age and older
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top